Fresenius Medical Care : FMC publishes preliminary outlook for 2019: A year of investment – We cut our TP to € 77
>Indicative 2019 outlook - Fresenius Medical Care (FME) published indicative and preliminary guidance for 2019: Solid revenue growth on a comparable basis and net income around the FY 2018 level on a comparable basis. The 2018 comparable basis is expected to be revenue of € 15,850-€ 16,050m, and net income of 1,350-1,365m. The implied outlook for 2019 adj. net income is below our estimate, mainly due to the higher investments that FME expects in 2019. The company str...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.